US settles three reverse payment fights with Teva units
Reprints
(Reuters) — The U.S. Federal Trade Commission has settled three reverse payment fights with units of Teva Pharmaceuticals Industries Ltd., the agency said on Tuesday.
Under the settlement agreement, Teva will be prohibited from reaching any reverse payment agreements with rivals.
In a reverse payment scheme, a brand name drug company compensates a generic firm if it agrees to delay in bringing the cheaper version of the drug to market.
Read Next
-
U.S. Supreme Court justices divided over Teva patent battle
(Reuters) — The U.S. Supreme Court on Wednesday appeared closely divided as it weighed Teva Pharmaceutical Industries Ltd.’s high-profile fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug.
